Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week oral administration to patients suffering from age-related SARcopenia, including sarcopenic obesity, Aged 65 years and at risk of mobility disability. A double-blind, placebo controlled, randomized INTerventional Clinical Trial (SARA-INT).
Sponsor: |
Biophytis |
Enrolling: |
Male and Female Patients |
Study Length: |
6 Months |
Clinic Visits: |
5 |
IRB Number: |
AAAS1712 |
U.S. Govt. ID: |
NCT03452488 |
Contact: |
Javier Narvaez: (212)305-0778 / sara_int@cumc.columbia.edu |
We are looking for people ages 65 and older to help us evaluate if an investigational drug improves muscle function, which can reduce risk of falls and fractures. To be considered for the study, you: 1. Must complete a pre-screening phone interview to assess your eligibility 2. If you are eligible, you will be invited to attend an in-person appointment at the research clinic. You will receive: $100 compensation for that first visit (and additional compensation for further visits if you qualify and agree to be followed for four additional in-person visits over 6 months), breakfast or lunch the day of your visits, travel costs (covered or reimbursed up to $50 per visit). If you know a family member or other person who may be interested in this study, you can also forward this information to them.
This study is closed
Investigator
Moise Desvarieux, MD, PhD
Are you 65 years or older? |
Yes |
No |
Are you living in the community (that is, not living in a nursing home, or assisted living facility)? |
Yes |
No |
Have you recently experienced physical fatigue, tiredness, or loss of strength or energy limiting your daily activities? |
Yes |
No |